New drug CLIO-8221 takes on advanced solid tumors in early trial
Disease control
Recruiting now
This study tests an experimental drug, CLIO-8221, in 306 adults with advanced solid tumors that have spread or cannot be removed. The first phase finds the safest dose, and the second phase checks how well the drug shrinks tumors. The goal is to control the disease, not cure it, …
Phase: PHASE1, PHASE2 • Sponsor: Callio Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC